Loading
Life sciences · Journal article
Journal of the Pediatric Infectious Diseases Society · September 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Despite advances in antiretroviral therapy, children living with HIV remain at increased risk for early cardiometabolic disease. Although second-generation integrase strand transfer inhibitors such as dolutegravir (DTG) have been associated with weight gain in adults, pediatric clinical trials have demonstrated a largely weight-neutral metabolic profile. Emerging observational data, however, report excess DTG-associated weight gain among children and adolescents living in increasingly obesogenic environments. As pediatric HIV epidemiology shifts from undernutrition toward a growing burden of obesity, HIV care should incorporate longitudinal metabolic monitoring, nutritional counseling, and continued research on the long-term cardiometabolic effects of DTG.